This open label French study enrolled 60 antiretroviral naïve patients, who had baseline plasma HIV RNA levels of greater than 25,000 copies/ml and CD4 counts greater than 200 cells/mm3. The median CD4 count at baseline was 434 cells/mm3, and HIV RNA 108,800 copies/ml. The mean viral load decrease was -1.9 logs by week 4 and continued through week 24; and 84% of the patients had plasma viral loads less than 500 copies/ml by week 16. The median CD4 cell increase was 129 by week 16. 22% of patients developed cutaneous rash with a mean of 15 days for rash to develop after drug initiation (range 3-26 days); this led to NVP discontinuation in 4/13 patients. 2 patients discontinued the regimen because of abnormal liver function tests. The presentation suggested that d4T, ddI, and nevirapine given in combination can be a very effective protease inhibitor sparing regimen, with minimal and manageable side effects.